Study of Changes in Biochemical Parameter Ca-125 in Ovarian Tumors before and after Chemotherapy

Introduction: The cancer burden in India is given in Gynaecological cancers occur in about 6.8% population. The lifetime risk of developing sporadic epithelial ovarian cancer is approximately 1.7% although patients with a familial predisposition have a much higher lifetime risk in the range of 10 to 40%. Serum CA125 is the only serum marker available with potential accuracy to be beneficial. But even this marker is less than optimal. Approximately 50% of patients with early-stage ovarian and other cancers do not have elevated serum CA125 levels. Also, a variety of nonmalignant and non ovarian malignant conditions can result in elevated serum CA125 levels. The current study designed with an aim to explore the changes in CA125 in malignant and benign ovarian tumours pre therapy and post therapy. To explore the differences in CA125 between healthy individuals and patients with ovarian tumors. Methodology: A case study control was conducted on 40 patients suffering from ovarian tumors (Benign and Malignant) who had reported to Rangaraya Medical College and hospital, Kakinada after ethical committee clearance and informed the consent from the patients. Results: All statistical analysis was done using SPSS software and results were obtained The mean age of the patients were found to be 44.77 ? 11.66. Mean age of the patients with malignant tumors (n=29) was 47.7 to ? 9.26 years whereas for benign tumors (n=11) it was only 37? 4.34 years. All patients with ovarian tumours (both malignant and benign) had a pretreatment mean ? SD value of CA125 of 767 ?1069 U/ml which reduced to a mean? SD value of 46.28 ? 41.28 U/ml post treatment (pless than 0.0004). Conclusion: The changes in CA125 levels were significant in both malignant and benign tumors thus reinforcing the importance of its role as a biomarker in ovarian neoplasm especially in epithelial ovarian cancers.